-
1
-
-
0033802496
-
Risk of mortality following clinical fractures
-
Cauley JA. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11: 556-61
-
(2000)
Osteoporos Int
, vol.11
, pp. 556-561
-
-
Cauley, J.A.1
-
3
-
-
0035406305
-
2001 Medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis
-
American Association of Clinical Endocrinologists
-
Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists. 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract. 2001; 7 (4): 293-312
-
(2001)
Endocr Pract.
, vol.7
, Issue.4
, pp. 293-312
-
-
Hodgson, S.F.1
Watts, N.B.2
Bilezikian, J.P.3
-
5
-
-
0034719619
-
Osteoporosis prevention, diagnosis and therapy
-
National Institutes of Health (USA). Osteoporosis prevention, diagnosis and therapy. NIH Consensus Statements 2000; 17 (1): 1-45
-
(2000)
NIH Consensus Statements
, vol.17
, Issue.1
, pp. 1-45
-
-
-
7
-
-
0029890161
-
Hip fracture
-
Zuckerman JD. Hip fracture. N Engl J Med 1996; 334: 1519-25
-
(1996)
N Engl J Med
, vol.334
, pp. 1519-1525
-
-
Zuckerman, J.D.1
-
8
-
-
0033550968
-
Mortality after all major types of osteoporotic fracture in men and women: An observational study
-
Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 878-82
-
(1999)
Lancet
, vol.353
, pp. 878-882
-
-
Center, J.R.1
Nguyen, T.V.2
Schneider, D.3
-
9
-
-
0033553866
-
Vertebral fractures and mortality in older women
-
Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women. Arch Intern Med 1999; 159: 1215-20
-
(1999)
Arch Intern Med
, vol.159
, pp. 1215-1220
-
-
Kado, D.M.1
Browner, W.S.2
Palermo, L.3
-
10
-
-
0026515737
-
Incidence of clinically diagnosed vertebral fractures: A population based study in Rochester, Minnesota, 1985-1989
-
Cooper C, Atkinson EJ, O'Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992; 7: 221-7
-
(1992)
J Bone Miner Res
, vol.7
, pp. 221-227
-
-
Cooper, C.1
Atkinson, E.J.2
O'Fallon, W.M.3
-
11
-
-
0035900949
-
Risk of new vertebral fracture in the year following a fracture
-
Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-3
-
(2001)
JAMA
, vol.285
, pp. 320-323
-
-
Lindsay, R.1
Silverman, S.L.2
Cooper, C.3
-
12
-
-
0034022318
-
Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis
-
Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 4: 721-39
-
(2000)
J Bone Miner Res
, vol.4
, pp. 721-739
-
-
Klotzbuecher, C.M.1
Ross, P.D.2
Landsman, P.B.3
-
13
-
-
0032951747
-
Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures
-
Black DM, Arden NK, Palmero L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res 1999; 14: 821-8
-
(1999)
J Bone Miner Res
, vol.14
, pp. 821-828
-
-
Black, D.M.1
Arden, N.K.2
Palmero, L.3
-
14
-
-
1642443292
-
Confronting osteoporosis: What we know, where we're headed
-
Davidson M, DeSimone ME. Confronting osteoporosis: what we know, where we're headed. Clin Rev 2002; 12: 76-82
-
(2002)
Clin Rev
, vol.12
, pp. 76-82
-
-
Davidson, M.1
DeSimone, M.E.2
-
15
-
-
0034707104
-
Prevention of hip fracture in elderly people with use of a hip protector
-
Kannus P, Parkkari J, Niemi S, et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 2000; 343: 1506-13
-
(2000)
N Engl J Med
, vol.343
, pp. 1506-1513
-
-
Kannus, P.1
Parkkari, J.2
Niemi, S.3
-
16
-
-
0028949069
-
Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial
-
Reid IR, Ames RW, Evans MC, et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 1995; 98: 331-5
-
(1995)
Am J Med
, vol.98
, pp. 331-335
-
-
Reid, I.R.1
Ames, R.W.2
Evans, M.C.3
-
17
-
-
0030826193
-
Calcium for prevention of osteoporotic fractures in postmenopausal women
-
Cumming RG, Nevitt MC. Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res 1997; 12: 1321-9
-
(1997)
J Bone Miner Res
, vol.12
, pp. 1321-1329
-
-
Cumming, R.G.1
Nevitt, M.C.2
-
18
-
-
0030763532
-
Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
-
Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-6
-
(1997)
N Engl J Med
, vol.337
, pp. 670-676
-
-
Dawson-Hughes, B.1
Harris, S.S.2
Krall, E.A.3
-
19
-
-
0031803314
-
The role of calcium and vitamin D in the prevention of osteoporosis
-
Reid IR. The role of calcium and vitamin D in the prevention of osteoporosis. Endocrinol Metab Clin North Am 1998; 27: 389-98
-
(1998)
Endocrinol Metab Clin North Am
, vol.27
, pp. 389-398
-
-
Reid, I.R.1
-
20
-
-
0030038417
-
Vitamin D supplementation and fracture incidence in elderly persons
-
Lips P, Graafmans WC, Ooms ME, et al. Vitamin D supplementation and fracture incidence in elderly persons. Ann Intern Med 1996; 124: 400-6
-
(1996)
Ann Intern Med
, vol.124
, pp. 400-406
-
-
Lips, P.1
Graafmans, W.C.2
Ooms, M.E.3
-
21
-
-
0031036965
-
Bisphosphonates: Preclinical aspects and use in osteoporosis
-
Fleisch HA. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 1997; 29: 55-62
-
(1997)
Ann Med
, vol.29
, pp. 55-62
-
-
Fleisch, H.A.1
-
22
-
-
0033065233
-
Bisphosphonates: From the laboratory to the clinic and back again
-
Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25: 97-106
-
(1999)
Bone
, vol.25
, pp. 97-106
-
-
Russell, R.G.1
Rogers, M.J.2
-
23
-
-
0032583492
-
Effect of alendronate on risk of fracture in women with low bone Associadensity but without vertebral fractures: Results from the Fracture Intervention Trial
-
Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone Associadensity but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82
-
(1998)
JAMA
, vol.280
, pp. 2077-2082
-
-
Cummings, S.R.1
Black, D.M.2
Thompson, D.E.3
-
24
-
-
0032896590
-
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
-
Fosamax International Trial Study Group
-
Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999; 9: 461-8
-
(1999)
Osteoporos Int
, vol.9
, pp. 461-468
-
-
Pols, H.A.1
Felsenberg, D.2
Hanley, D.A.3
-
25
-
-
0033552255
-
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
-
Vertebral Efficacy With Risedronate Therapy (VERT) Study Group
-
Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-52
-
(1999)
JAMA
, vol.282
, pp. 1344-1352
-
-
Harris, S.T.1
Watts, N.B.2
Genant, H.K.3
-
26
-
-
0029116697
-
Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
-
Chesnut III CH, McClung M, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99: 144-52
-
(1995)
Am J Med
, vol.99
, pp. 144-152
-
-
Chesnut III, C.H.1
McClung, M.2
Ensrud, K.E.3
-
27
-
-
0028851590
-
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
-
Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43
-
(1995)
N Engl J Med
, vol.333
, pp. 1437-1443
-
-
Liberman, U.A.1
Weiss, S.R.2
Broll, J.3
-
28
-
-
0032767389
-
Alendronate increases bone density and bone strength at the distal radius in postmenopausal women
-
Schneider PF, Fischer M, Allolio B, et al. Alendronate increases bone density and bone strength at the distal radius in postmenopausal women. J Bone Miner Res 1999; 14: 1387-93
-
(1999)
J Bone Miner Res
, vol.14
, pp. 1387-1393
-
-
Schneider, P.F.1
Fischer, M.2
Allolio, B.3
-
29
-
-
0004851872
-
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group
-
Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41
-
(1996)
Lancet
, vol.348
, pp. 1535-1541
-
-
Black, D.M.1
Cummings, S.R.2
Karpf, D.B.3
-
30
-
-
0034097152
-
Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis
-
Milano
-
Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Aging (Milano) 2000; 12: 1-12
-
(2000)
Aging
, vol.12
, pp. 1-12
-
-
Schnitzer, T.1
Bone, H.G.2
Crepaldi, G.3
-
31
-
-
0036828449
-
Alendronate Once-Weekly Study Group: Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis
-
Rizzoli R, Greenspan SL, Bone III G, et al. Alendronate Once-Weekly Study Group: two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17 (11): 1988-96
-
(2002)
J Bone Miner Res
, vol.17
, Issue.11
, pp. 1988-1996
-
-
Rizzoli, R.1
Greenspan, S.L.2
Bone III, G.3
-
32
-
-
12144289279
-
Alendronate Phase III Osteoporosis Treatment Study Group: Ten years' experience with alendronate for osteoporosis in postmenopausal women
-
Bone HG, Hosking D, Devogelaer JP, et al. Alendronate Phase III Osteoporosis Treatment Study Group: ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350 (12): 1189-99
-
(2004)
N Engl J Med
, vol.350
, Issue.12
, pp. 1189-1199
-
-
Bone, H.G.1
Hosking, D.2
Devogelaer, J.P.3
-
33
-
-
0030868816
-
Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis
-
Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100: 1475-80
-
(1997)
J Clin Invest
, vol.100
, pp. 1475-1480
-
-
Chavassieux, P.M.1
Arlot, M.E.2
Reda, C.3
-
34
-
-
0033755981
-
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
-
Boivin GY, Chavassieux PM, Santora AC, et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000; 27: 687-94
-
(2000)
Bone
, vol.27
, pp. 687-694
-
-
Boivin, G.Y.1
Chavassieux, P.M.2
Santora, A.C.3
-
35
-
-
0035996567
-
Changes in bone remodeling rate influence the degree of mineralization of bone
-
Boivin G, Meunier PJ. Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res 2002; 43: 535-7
-
(2002)
Connect Tissue Res
, vol.43
, pp. 535-537
-
-
Boivin, G.1
Meunier, P.J.2
-
36
-
-
14644399915
-
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension
-
Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004; 19: 1259-69
-
(2004)
J Bone Miner Res
, vol.19
, pp. 1259-1269
-
-
Ensrud, K.E.1
Barrett-Connor, E.L.2
Schwartz, A.3
-
37
-
-
0037156445
-
Gastric and duodenal safety of daily alendronate
-
Apr 22
-
Donahue JG, Chan KA, Andrade SE, et al. Gastric and duodenal safety of daily alendronate. Arch Intern Med 2002 Apr 22; 162 (8): 936-42
-
(2002)
Arch Intern Med
, vol.162
, Issue.8
, pp. 936-942
-
-
Donahue, J.G.1
Chan, K.A.2
Andrade, S.E.3
-
39
-
-
0035253489
-
Effects of risedronate on the risk of hip fracture in elderly women
-
McClung MR, Geusens P, Miller PD, et al. Effects of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-40
-
(2001)
N Engl J Med
, vol.344
, pp. 333-340
-
-
McClung, M.R.1
Geusens, P.2
Miller, P.D.3
-
40
-
-
0031057249
-
Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study
-
Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997; 15: 955-62
-
(1997)
J Clin Oncol
, vol.15
, pp. 955-962
-
-
Delmas, P.D.1
Balena, R.2
Confravreux, E.3
-
41
-
-
12944291524
-
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
-
Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83-91
-
(2000)
Osteoporos Int
, vol.11
, pp. 83-91
-
-
Reginster, J.Y.1
Minne, H.W.2
Sorensen, O.H.3
-
42
-
-
0037326110
-
Risedronate prevents new vertebral fractures in postmenopausal women at high risk
-
Watts NB, Josse RG, Hamdy RC, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. JCEM 2003; 88: 542-9
-
(2003)
JCEM
, vol.88
, pp. 542-549
-
-
Watts, N.B.1
Josse, R.G.2
Hamdy, R.C.3
-
43
-
-
11144354206
-
Efficacy of risedronate on clinical vertebral fractures within six months
-
Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004; 20 (4): 433-9
-
(2004)
Curr Med Res Opin
, vol.20
, Issue.4
, pp. 433-439
-
-
Roux, C.1
Seeman, E.2
Eastell, R.3
-
44
-
-
1342281219
-
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis
-
Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 74 (2): 129-35
-
(2004)
Calcif Tissue Int
, vol.74
, Issue.2
, pp. 129-135
-
-
Harrington, J.T.1
Ste-Marie, L.G.2
Brandi, M.L.3
-
45
-
-
0036690206
-
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis
-
Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103-11
-
(2002)
Calcif Tissue Int
, vol.71
, pp. 103-111
-
-
Brown, J.P.1
Kendler, D.L.2
McClung, M.R.3
-
46
-
-
0037291756
-
Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience
-
Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003; 32 (2): 120-6
-
(2003)
Bone
, vol.32
, Issue.2
, pp. 120-126
-
-
Sorensen, O.H.1
Crawford, G.M.2
Mulder, H.3
-
47
-
-
12944323192
-
Seven years of treatment with risedronate in women with postmenopausal osteoporosis
-
Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75 (6): 462-8
-
(2004)
Calcif Tissue Int
, vol.75
, Issue.6
, pp. 462-468
-
-
Mellstrom, D.D.1
Sorensen, O.H.2
Goemaere, S.3
-
49
-
-
0033016224
-
Effect of calcitonin on vertebral and other fractures
-
Kanis JA, McCloskey EV. Effect of calcitonin on vertebral and other fractures. QJM 1999; 92: 143-9
-
(1999)
QJM
, vol.92
, pp. 143-149
-
-
Kanis, J.A.1
McCloskey, E.V.2
-
50
-
-
0033829969
-
A randomized trial of nasal spray salmon calcitonin in postmenopausal wo-men with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study
-
Chesnut III CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal wo-men with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000; 109: 267-76
-
(2000)
Am J Med
, vol.109
, pp. 267-276
-
-
Chesnut III, C.H.1
Silverman, S.2
Andriano, K.3
-
51
-
-
0036852676
-
The analgesic role of calcitonin follow-ing osteoporotic fracture
-
Silverman SL, Azria M. The analgesic role of calcitonin follow-ing osteoporotic fracture. Osteoporos Int 2002; 13: 858-67
-
(2002)
Osteoporos Int
, vol.13
, pp. 858-867
-
-
Silverman, S.L.1
Azria, M.2
-
52
-
-
0033431687
-
Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: A prospective double-blind, randomized, placebo-controlled clinical study
-
Lyritis GP, Ioannidis GV, Karachalios T, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 1999; 15: 284-9
-
(1999)
Clin J Pain
, vol.15
, pp. 284-289
-
-
Lyritis, G.P.1
Ioannidis, G.V.2
Karachalios, T.3
-
54
-
-
0032416079
-
Selective estrogen receptors modulators: A new category of therapeutic agents for extending the health of postmenopausal women
-
Goldstein SR. Selective estrogen receptors modulators: a new category of therapeutic agents for extending the health of postmenopausal women. Am J Obstet Gynecol 1998; 179: 1479-8
-
(1998)
Am J Obstet Gynecol
, vol.179
, pp. 1479-1488
-
-
Goldstein, S.R.1
-
55
-
-
0033515045
-
Clinical effects of raloxifene hydrochloride in women
-
Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 1999; 130: 431-9
-
(1999)
Ann Intern Med
, vol.130
, pp. 431-439
-
-
Khovidhunkit, W.1
Shoback, D.M.2
-
56
-
-
2642712522
-
Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
-
Walsh BW, Kuller LH, Wild R, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445-51
-
(1998)
JAMA
, vol.279
, pp. 1445-1451
-
-
Walsh, B.W.1
Kuller, L.H.2
Wild, R.3
-
57
-
-
0033581212
-
Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
-
Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637-45
-
(1999)
JAMA
, vol.282
, pp. 637-645
-
-
Ettinger, B.1
Black, D.M.2
Mitlak, B.H.3
-
58
-
-
0033575083
-
The effect of raloxifene on risk of breast cancer in postmenopausal women
-
Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 281: 2189-97
-
(1999)
JAMA
, vol.281
, pp. 2189-2197
-
-
Cummings, S.R.1
Eckert, S.2
Krueger, K.A.3
-
59
-
-
2642712522
-
Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
-
Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445-51
-
(1998)
JAMA
, vol.279
, pp. 1445-1451
-
-
Walsh, B.W.1
Kuller, L.H.2
Wild, R.A.3
-
60
-
-
0030015080
-
A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
-
Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11: 835-42
-
(1996)
J Bone Miner Res
, vol.11
, pp. 835-842
-
-
Draper, M.W.1
Flowers, D.E.2
Huster, W.J.3
-
61
-
-
0030664688
-
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
-
Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-7
-
(1997)
N Engl J Med
, vol.337
, pp. 1641-1647
-
-
Delmas, P.D.1
Bjarnason, N.H.2
Mitlak, B.H.3
-
62
-
-
32744462785
-
Osteoporosis indication approval recommended with restrictions: FDA Endocrinological and Metabolic Drugs Advisory Committee
-
Jul 30
-
Lilly Forteo. Osteoporosis indication approval recommended with restrictions: FDA Endocrinological and Metabolic Drugs Advisory Committee. Pink Sheet 2001 Jul 30; 63 (31): 3
-
(2001)
Pink Sheet
, vol.63
, Issue.31
, pp. 3
-
-
Forteo, L.1
-
63
-
-
0032746174
-
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
-
Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 439-46
-
(1999)
J Clin Invest
, vol.104
, pp. 439-446
-
-
Jilka, R.L.1
Weinstein, R.S.2
Bellido, T.3
-
64
-
-
0035837553
-
Effect of parathyroid hormone (1-34) on fracture and bone mineral density in postmenopausal women with osteoporosis
-
Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fracture and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41
-
(2001)
N Engl J Med
, vol.344
, pp. 1434-1441
-
-
Neer, R.M.1
Arnaud, C.D.2
Zanchetta, J.R.3
-
65
-
-
3242762388
-
Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
-
Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004; 19 (5): 745-51
-
(2004)
J Bone Miner Res
, vol.19
, Issue.5
, pp. 745-751
-
-
Ettinger, B.1
San Martin, J.2
Crans, G.3
-
66
-
-
0037186926
-
Intravenous zoledronic acid in postmenopausal women with low bone mineral density
-
Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-61
-
(2002)
N Engl J Med
, vol.346
, pp. 653-661
-
-
Reid, I.R.1
Brown, J.P.2
Burckhardt, P.3
-
67
-
-
4544262219
-
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
-
Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-9
-
(2004)
J Bone Miner Res
, vol.19
, pp. 1241-1249
-
-
Chesnut III, C.H.1
Skag, A.2
Christiansen, C.3
-
68
-
-
9144233479
-
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis
-
Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350 (5): 459-68
-
(2004)
N Engl J Med
, vol.350
, Issue.5
, pp. 459-468
-
-
Meunier, P.J.1
Roux, C.2
Seeman, E.3
|